Tests INCA033989 Against Standard Care in Essential Thrombocythemia
Tests INCA033989 against standard treatment in adults with essential thrombocythemia and a CALR mutation.
Plain-language title generated from the registry record
Registry title: A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
Key facts
- Where
- Hamilton, Kingston, Montreal, Québec, Toronto, and Vancouver, CanadaSee the 7 sites
- Phase
- Phase 3
Where in Canada
- Juravinski Cancer Centre-Hamilton Health Sciences (Hhs)Hamilton, CanadaNot yet recruiting
- Queens University, Kingston General Hospital (Kgh), Kingston Health Sciences Centre (Khsc)Kingston, CanadaNot yet recruiting
- McGill University Health Centre - Glen Site, Centre For Innovative MedicineMontreal, CanadaNot yet recruiting
- Sir Mortimer B Davis - Jewish General HospitalMontreal, CanadaNot yet recruiting
- Hotel-Dieu de LevisQuébec, CanadaNot yet recruiting
- University Health Network UHN Princess Margaret Cancer CentreToronto, CanadaNot yet recruiting
- St. Paul'S Hospital (Sph), Providence Health Care, University of British ColumbiaVancouver, CanadaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Incyte Corporation
- Trial code
- NCT07623200EU 2026-525398-38-00
- Record updated
- 5 November 2026
- Original description
This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.Read full original descriptionShow less
A Phase 3, Randomized, Open-Label Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia and a CALR Mutation Previously Treated With Cytoreductive Therapy (EXCALIBUR-ET2)
This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.
Inclusion: Confirmed diagnosis of high-risk ET; Presence of mutCALR; Prior treatment with at least 1 cytoreductive therapy.
Exclusion: Major bleeding or thrombosis within the last 3 months prior to study enrollment; Any prior allogenic or autologous stem-cell transplantation; Unresolved toxicity ≥ Grade 2 from previous therapy except for stable chronic toxicities (Grade 2) not expected to resolve, such as stable Grade 2 peripheral neuropathy; Prior nonhematologic malignancy except for the following: Malignancy treated with curative intent and with no evidence of active disease for more than 2 years before screening. Adequately treated carcinoma in situ without current evidence of disease; Other protocol-defined Inclusion/Exclusion Criteria apply; Presence of any hematologic malignancy other than ET.